1James C, Ugo V, Le Cou6dic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [ J ]. Nature, 2005, 434 ( 7037 ) : 1 144-1148.
2Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [ J ]. Lancet, 2005, 365 ( 9464 ) : 1054-1061.
3Levine RL, Wadleigh M, Cools J, et al. Activiting mutation in thetyrosine kinase JAK2 polycythaemia vera, essential thrombythemia, and myeloid metaplasia with myelofibrosis [ J ]. Cancer Cell, 2005, 7 ( 4 ) : 387-397.
4Kralavics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorde [ J]. N Engl J Med, 2005, 352( 17 ) : 1779-1790.
5Harrison C, Kiladjian JJ, A1-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis [ J]. N Engl J Med, 2012, 366 (9): 787-798.
6Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? [ J ]. Hematology Am Soc Hematol Educ Program, 2014, 2014 ( 1 ) : 268-276.
7Nangalia J, Green TR. The evoloving gemomic landscape of myeloproliferative neoplasms [ J ]. Hematology Am Soe Hematol Educ Program, 2014, 2014 ( 1 ) : 287-296.
8Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms [ J ]. N Engl J Med, 2013, 369( 25 ): 2379-2390.
10Mullally A, Bruedigam C, Poveromo L, et al. Depletion of JAK2V617F myeloproliferative neoplasm-propagating stem cells by interferon-a in a murine model of polycythemia vera [ J ]. Blood, 2013, 121 ( 18 ) : 3692-3702.
